London, Feb 23, 2026, 07:50 GMT — Premarket
- GSK repurchased 467,000 shares on Feb. 20, paying an average of 2,223.53 pence apiece.
- Shares settled at 2,213.00 pence, slipping 0.58% for the session.
- Investors now have their eyes on how fast buybacks are coming in, with the next set of quarterly results due April 29.
GSK caught attention before London’s open Monday as it flagged fresh buybacks in its ongoing program. The company reported it snapped up 467,000 ordinary shares on Feb. 20, with prices spanning from 2,200.00 to 2,242.00 pence apiece. The volume-weighted average ticked in at 2,223.53 pence.
The company’s buyback stands out as one of the few notable signals for traders this week. Buybacks pare down share counts and may give a lift to earnings per share, but they seldom move the broader mood by themselves.
GSK slipped 0.58% to finish at 2,213.00 pence on Friday, moving within a range from 2,200.00 pence up to 2,243.00 pence during the session, according to recent trading data.
These repurchases are part of GSK’s broader £2 billion buyback program, set to continue until the close of the second quarter of 2026. In a Feb. 17 filing, GSK disclosed the fourth tranche, capped at £0.45 billion, is slated to run through April 24. BNP Paribas will handle trades independently, sticking to agreed parameters.
GSK’s U.S. ADRs wrapped up Friday at $59.52 in New York, dropping 2.19%. That gives U.S. investors a softer starting point for Monday, compared to London’s previous close.
The stock just passed its most recent dividend date. GSK’s Q4 2025 payout went ex-dividend on Feb. 19 for ordinary shares, with investors set to receive payment on April 9, per the company’s dividend calendar.
Still, buybacks and dividends don’t answer the main issue dogging the stock: how quickly GSK can fill the hole as patents expire and keep momentum, especially with pricing and vaccine demand in flux. CEO Luke Miels, speaking to Reuters earlier this month, said, “We need to accelerate what we have and to add to it via smart business development.” The company’s plan leans on bolt-on acquisitions and ramping up R&D. Reuters
The risk for holders is clear enough: should markets start doubting that the pipeline and deal activity can bridge the post-patent gap fast, this buyback starts to look more like a patch job than a real floor. GSK, too, remains vulnerable to swings in the wider healthcare space and sudden policy headlines that can rattle the sector.
In the coming week, traders will be eyeing buyback disclosures, looking for signs about both timing and pricing discipline. They’ll also be watching to see if the stock can stay above recent support levels following Friday’s slip. Moves across U.K. equities could quickly make themselves felt in a FTSE heavyweight such as GSK.
GSK is slated to release its first-quarter results on Wednesday, April 29, marking the next scheduled date on the company’s calendar.
